Zobrazeno 1 - 10
of 142
pro vyhledávání: '"William J Gullick"'
Autor:
Emily Saintas, Liam Abrahams, Gulshan T Ahmad, Anu-Oluwa M Ajakaiye, Abdulaziz S H A M AlHumaidi, Candice Ashmore-Harris, Iain Clark, Usha K Dura, Carine N Fixmer, Chinedu Ike-Morris, Mireia Mato Prado, Danielle Mccullough, Shishir Mishra, Katia M U Schöler, Husne Timur, Maxwell D C Williamson, Markella Alatsatianos, Basma Bahsoun, Edith Blackburn, Catherine E Hogwood, Pamela E Lithgow, Michelle Rowe, Lyto Yiangou, Florian Rothweiler, Jindrich Cinatl, Richard Zehner, Anthony J Baines, Michelle D Garrett, Campbell W Gourlay, Darren K Griffin, William J Gullick, Emma Hargreaves, Mark J Howard, Daniel R Lloyd, Jeremy S Rossman, C Mark Smales, Anastasios D Tsaousis, Tobias von der Haar, Mark N Wass, Martin Michaelis
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172140 (2017)
The formation of acquired drug resistance is a major reason for the failure of anti-cancer therapies after initial response. Here, we introduce a novel model of acquired oxaliplatin resistance, a sub-line of the non-MYCN-amplified neuroblastoma cell
Externí odkaz:
https://doaj.org/article/ef8bcb9439b04f71b952d9ed30ce9beb
Autor:
Paul A. W. Edwards, Daniel Birnbaum, Max Chaffanet, Carlos Caldas, Jocelyne Jacquemier, William J. Gullick, Stephen M. Hewitt, Grace M. Callagy, Jessica C. Pole, Maria J. Garcia, N. Gopalakrishna Iyer, José Adélaïde, Valérie-Jeanne Bardou, Christophe Ginestier, Suet-Feung Chin, Huai-En Huang
Supplementary Table 1 from A Recurrent Chromosome Breakpoint in Breast Cancer at the NRG1/Neuregulin 1/Heregulin Gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd92426bd91b1ccb368a92ff44a7fb47
https://doi.org/10.1158/0008-5472.22363997.v1
https://doi.org/10.1158/0008-5472.22363997.v1
Publikováno v:
Cancer Research. 71:P1-07
Background: The Human Epidermal Growth Factor Receptor 2 (HER2) is overexpressed in 18–20% of breast cancers. Herceptin is an effective drug for the treatment of breast cancers expressing high levels of HER2. It is well known that there is a correl
Publikováno v:
Experimental Cell Research. 317:423-432
Neuregulins are growth factors that signal via the ErbB3 and ErbB4 receptors. Here we show using immunohistochemistry that they are often expressed in the nucleus of a range of tumour types including soft tissue and breast. The Neuregulin 1 type I-β
Autor:
William J. Gullick
Publikováno v:
European Journal of Cancer. 45:205-210
Multicellular organisms have evolved systems to allow information to be exchanged between cells in tissues. One example of these utilises proteins or peptides which are synthesised and released under stringent controls from one cell which then diffus
Publikováno v:
Oncogene. 27:715-720
The NRG4 gene is a member of a family of four genes that encode a class of epidermal growth factors. This gene has been reported to express a protein designated here as NRG4A1. We describe here a novel splice variant of the NRG4 gene, NRG4A2, which e
Autor:
C.M. McClelland, William J. Gullick
Publikováno v:
British Journal of Cancer
Epidermal growth factor receptor is a potential target for cancer treatment and new small-molecule tyrosine kinase inhibitor drugs have been designed to inhibit its activity. In this work we identify potential surrogate markers of drug activity using
Autor:
Nicola Normanno, William J. Gullick
Publikováno v:
Endocrine-Related Cancer. 13:3-6
The paper by Angelucci et al. published in the current issue of Endocrine-Related Cancer suggests a potential, novel application of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of bone metastases. Interesti
Publikováno v:
Breast Cancer Research and Treatment. 96:163-168
A new family of epidermal growth factor-like proteins, the Neuregulins (NRGs), have recently been identified and are expressed in a range of normal tissues and in some forms of cancer including breast cancer. In this study we examined using immunohis
Autor:
Peter Barrett-Lee, Lesley-Ann Martin, John F.R. Robertson, William J. Gullick, S.R.D. Johnston, Helen E. Jones, Richard J. Santen, Robert Ian Nicholson, William R. Miller, A. E. Wakeling, Mitchell Dowsett, Ross Duncan, Christopher C. Benz, Fortunato Ciardiello, Robert L. Sutherland, Anthony Howell, Julia Margaret Wendy Gee
Publikováno v:
Endocrine-Related Cancer. 12:S1-S7
Anti-hormones (notably tamoxifen), chemotherapy and modern radiotherapeutic approaches are invaluable in the management of breast cancer, and collectively have contributed substantially to the improved survival in this disease. Moreover, there is pro